June 28, 2012 – ECI Biotech (ECI), has just received IRB approval from a leading research hospital in the Midwest and a notice of grant award from the National Institute of Allergy and Infectious Diseases (NIAID) at National Institute of Health (NIH), to perform clinical testing on ECI’s rapid in vitro diagnostic for periprosthetic joint infections (Phase I SBIR award,1 R43 AI100502-01, $298,291).
DATELINE: Amsterdam, Netherlands — May 23, 2012 —ASLI A/S and ECI Biotech unveil their first joint product offering, a hygiene sensor product for consumers that indicates when a kitchen sponge or wipe is no longer clean. The product was announced at the International Private Label Manufacturers Association Trade Show at the RAI Convention Center in Amsterdam.
Paid Summer Internships to Students Interested in Pursuing Careers in Life Sciences
DATELINE: WORCESTER, MA — June 14, 2011 — ECI Biotech (ECI), an innovative developer of the patented ExpressDetect® rapid infection sensors that will ultimately transform the way pathogens are detected in professional and OTC markets, is one of the select life sciences
companies in the Commonwealth participating in the Massachusetts Life Sciences Center (“the Center”) Internship Challenge Program. During the summer of 2011, ECI will provide practical experience to four full-time interns as part of its STEM workforce development program.
WORCESTER, MA —March 24, 2011 — ECI Biotech (ECI), an innovative developer and manufacturer of the patented ExpressDetect® rapid infection sensors that will ultimately transform the way pathogens are detected in professional and OTC markets, has been selected as a 2011 Accelerator Program Awardee from the Massachusetts Life Sciences Center, a quasi-public agency tasked with implementing the State’s $1 billion Life Sciences Initiative.
MASSDEVICE ON CALL — The Mass. Life Sciences Center, a quasi-public agency that oversees state dollars allocated toward increasing the life sciences industry’s footprint in the Bay State, doled out another $3.8 million in “accelerator” loans.
The program is designed to provide a boost to early-stage life science companies that the center’s scientific advisory board deems to have a high potential for commercialization, rapid growth and the ability to raise substantial capital.
ECI Biotech Inc. signed a licensing and manufacturing agreement with Systagenix Wound Management Inc.
Worcester, Mass.-based ECI Biotech makes protein-based, point-of-care bacterial sensors and will collaborate with Quincy, Mass.-based Systagenix to develop a diagnostic technology for treating chronic wounds.
The companies said the resulting product will enable early infection detection and cheaper care by reducing unnecessary blanket treatments.